Current immunotherapy for solid tumors

Immunotherapy

Volumn 1, Issue 3, 2009, Pages 483-493

  Barkholt, Lisbeth ^a   Bregni, Marco ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b San Giuseppe Hospital   (Italy)

Author keywords

Bone marrow transplantation; Immunotherapy; Lymphocyte; Tumor antigen

Indexed keywords

BEVACIZUMAB; CD3 ANTIGEN; CETUXIMAB; GAMMA INTERFERON; HLA B7 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 7; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB;

CANCER IMMUNOTHERAPY; CANCER RESEARCH; DNA MODIFICATION; DONOR LYMPHOCYTE INFUSION; DRUG LEGISLATION; GOOD MANUFACTURING PRACTICE; HELPER CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MELANOMA; NATURAL KILLER T CELL; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; TRANSGENES; TUMOR ESCAPE;

EID: 77953416908     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.13     Document Type: Review

References (79)

1. Storb R: Allogeneic hematopoietic stem cell transplantation - yesterday, today, and tomorrow. Exp. Hematol. 31(1), 1-10 (2003).
2. Demirer T, Barkholt L, Blaise D et al.: Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat. Clin. Pract. Oncol. 5(5), 256-267 (2008).
3. Didot A: Essai sur la prophylaxis du cancer. Bull. Acad. R. Sol. Belge. 11, 100-172 (1851).
4. Gross L: Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 3, 326-330 (1943).
5. Nadler SH, Moore GE: Clinical immunologic study of malignant disease: response to tumor transplants and transfer of leukocytes. Ann. Surg. 164(3), 482-490 (1966).
6. +, LAK cell clones to produce interferon-γ and tumor necrosis factor upon stimulation with tumor targets. Cancer Immunol. Immunother. 29(4), 270-278 (1989).
7. Mazumder A, Eberlein TJ, Grimm EA et al.: Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 53(A), 896-905 (1984). (Pubitemid 14183750)
8. Rosenberg SA: Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J. Biol. Response Mod. 3(5), 501-511 (1984). ■■ First results on series of Phase I studies demonstrating that systemic injection of activated killer cells can be safely administered in conjunction with IL-2 to humans with advanced cancer.
9. Bordignon C, Carlo-Stella C, Colombo MP et al.: Cell therapy: achievements and perspectives. Haematologica 84(12), 1110-1149 (1999).
10. Kammula US, Marincola FM: Cancer immunotherapy: is there real progress at last? BioDrugs 11(4), 249-260 (1999).
11. Yang JC, Childs R: Immunotherapy for renal cell cancer. J. Clin. Oncol. 24(35), 5576-5583 (2006).
12. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153(4), 1687-1696 (1994).
13. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS: A Phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transplant. 11(3), 181-187 (2005).
14. Frohn C: Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma. J. Immunother. 23, 499-504 (2000).
15. Passweg JR, Tichelli A, Meyer-Monard S et al.: Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18(11), 1835-1838 (2004).
16. Ishikawa E, Tsuboi K, Saijo K et al.: Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 24(3b), 1861-1871 (2004).
17. Krause SW, Gastpar R, Andreesen R et al.: Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical Phase I trial. Clin. Cancer Res. 10(11), 3699-3707 (2004).
18. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al.: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8), 3051-3057 (2005). ■■ First publication on safety and in vivo expansion of haploidentical, related-donor natural killer (NK)-cell infusions together with subcutaneous IL-2 injections in a non-hematopoietic stem cell transplantation setting after pretreatment with low- and high-dose regimens (cyclophosphamide, methylprednisolon and fludarabine) in poor-prognosis acute myeloid leukemia. (Pubitemid 40504320)
19. + NK cells in GMP-compliant conditions
20. Koehl U, Esser R, Zimmermann S et al.: Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin. Padiatr. 217(6), 345-350 (2005).
21. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A: Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr. Opin. Immunol. 17(2), 211-217 (2005). ■■ Comprehensive review that focuses on the role of alloreactive NK cells in adoptive immunotherapy of leukemia in the context of allogeneic hematopoietic transplantation.
22. Terunuma H, Deng X, Dewan Z, Fujimoto S, Yamamoto N: Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int. Rev. Immunol. 27(3), 93-110 (2008).
23. Alici E, Sutlu T, Bjorkstrand B et al.: Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 111(6), 3155-3162 (2008).
24. Dewan MZ, Terunuma H, Takada M et al.: Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo. Breast Cancer Res. Treat. 104(3), 267-275 (2007).
25. Brand JM, Meller B, Von Hof K et al.: Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev. 13(3), 307-314 (2004). (Pubitemid 38738372)
26. Dewan MZ, Terunuma H, Ahmed S et al.: Natural killer cells in breast cancer cell growth and metastasis in SCID mice. Biomed. Pharmacother. 59 (Suppl. 2), S375-S379 (2005).
27. Guimaraes F, Guven H, Donati D et al.: Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice. Leukemia 20(5), 833-839 (2006).
28. Khammari A, Nguyen JM, Pandolfino MC et al.: Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol, Immunother. 56(11), 1853-1860 (2007).
29. Dudley ME, Wunderlich JR, Yang JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
30. + T cells. J. Exp. Med. 202(7), 907-912 (2005).
31. Dudley ME, Yang JC, Sherry R et al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233-5239 (2008).
32. Kolb HJ, Mittermuller J, Clemm C et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76(12), 2462-2465 (1990).
33. Slavin S, Naparstek E, Nagler A et al.: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87(6), 2195-2204 (1996). (Pubitemid 26086858)
34. Guglielmi C, Arcese W, Dazzi F et al.: Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 100(2), 397-405 (2002). (Pubitemid 34761099)
35. Mackinnon S, Papadopoulos EB, Carabasi MH et al.: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86(A), 1261-1268 (1995).
36. Slavin S, Morecki S, Weiss L, Or R: Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J. Hematother. Stem Cell Res. 11(2), 265-276 (2002).
37. Bonini C, Ferrari G, Verzeletti S et al.: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276(5319), 1719-1724 (1997). (Pubitemid 27421983)
38. Alyea E, Schlossman R, Canning C et al.: CD8 depleted donor lymphocyte infusions mediate graft-versus-myeloma effect. Blood 88, 25a (1996).
39. Giralt S, Hester J, Huh Y et al.: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86 (11), 4337-4343 (1995).
40. Barkholt L, Bregni M, Remberger M et al.: Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann. Oncol. 17(7), 1134-1140 (2006). ■ Report on European multicenter study on allogeneic hematopoietic stem cell transplantation using reduced conditioning and donor lymphocyte infusions in metastatic renal cell cancer that confirms the pioneer results of the US NIH [76,77].
41. Bregni M, Dodero A, Peccatori J et al.: Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99(11), 4234-4236 (2002). (Pubitemid 35332074)
42. Kalos M: Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine 21(7-8), 781-786 (2003).
43. Parmiani G, Russo V, Marrari A et al.: Universal and sternness-related tumor antigens: potential use in cancer immunotherapy. Clin. Cancer Res. 13(19), 5675-5679 (2007).
44. Leen AM, Rooney CM, Foster AE: Improving T cell therapy for cancer. Annu. Rev. Immunol. 25, 243-265 (2007).
45. Dudley ME, Wunderlich JR, Robbins PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002).
46. Yee C, Thompson JA, Roche P et al.: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192(11), 1637-1644 (2000).
47. Rosenberg SA, Spiess P, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233 (4770), 1318-1321 (1986). ■■ Presentation of preclinical studies on a cell population that can be obtained from tumor-bearing animals and demonstrated to be more potent than lymphokine-activated killer cells when used for adoptive immunotherapy. These tumor-infiltrating lymphocytes were also able to be extracted from a variety of resected human tumors (e.g., melanoma and renal cell cancer) to be later tested in clinical trials, together with IL-2, in humans for their therapeutic efficacy. (Pubitemid 16002234)
48. + T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24(31), 5060-5069 (2006).
49. Morgan RA, Dudley ME, Wunderlich JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (5796), 126-129 (2006).
50. Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL: Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res. 60(13), 3542-3549 (2000). (Pubitemid 30482175)
51. + T cells for efficient tumor cell lysis. Cancer Res. 60(16), 4446-4452 (2000).
52. Kurokawa T, Oelke M, Mackensen A: Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int. J. Cancer 91(6), 749-756 (2001). (Pubitemid 32178640)
53. Nencioni A, Grunebach F, Schmidt SM et al.: The use of dendritic cells in cancer immunotherapy. Crit. Rev. Oncol. Hematol. 65(3), 191-199 (2008). ■ Review on dendiritc cell (DC)-based antitumor immunotherapy describing methodology (e.g., ex vivo DC generation and loading with antigens, used for ex vivo expansion of antitumor lymphocytes) and clinical trials where use in the adjuvant setting seems to be beneficial in solid cancer.
54. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F: Kinetics of dendritic cell activation: impact on priming of Th1, Th2 and nonpolarized T cells. Nat. Immunol. 1(4), 311-316 (2000).
55. Hess AD, Thoburn CJ: Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. Immunol. Rev. 157, 111-123 (1997).
56. Hess AD, Bright EC, Thoburn C et al.: Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood 89(6), 2203-2209 (1997). (Pubitemid 27132139)
57. Gryn J, Johnson E, Goldman N et al.: The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon. Bone Marrow Transplant 19(3), 221-226 (1997). (Pubitemid 27077476)
58. Kennedy MJ, Vogelsang GB, Jones RJ et al.: Phase I trial of interferon γ to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J. Clin. Oncol. 12(2), 249-257 (1994).
59. Byrne JL, Carter GI, Ellis I, Haynes AP, Russell NH: Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect. Bone Marrow Transplant 20(6), 517-520 (1997). (Pubitemid 27434903)
60. Disis ML, Gooley TA, Rinn K et al.: Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20(11), 2624-2632 (2002).
61. Knutson KL, Disis ML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. lmmunother. 54(8), 721-728 (2005).
62. Nanda NK, Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell 82(1), 13-17 (1995).
63. Morgan DJ, Kreuwel HT, Fleck S et al.: Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160(2), 643-651 (1998). (Pubitemid 28049303)
64. Peoples GE, Smith RC, Linehan DC et al.: Shared T cell epitopes in epithelial tumors. Cell Immunol. 164(2), 279-286 (1995).
65. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ: Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J. Immunol. 152(5), 2393-2400 (1994). (Pubitemid 24097931)
66. Dermime S, Mavroudis D, Jiang YZ et al.: Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 19(10), 989-999 (1997). (Pubitemid 27232175)
67. Butz EA, Bevan MJ: Differential presentation of the same M HC class I epitopes by fibroblasts and dendritic cells. J. Immunol. 160(5), 2139-2144 (1998).
68. Schlom J, Gulley JL, Arlen PM: Paradigm shifts in cancer vaccine therapy. Exp. Biol. Med. (Maywood). 233(5), 522-534 (2008). ■■ Review on cancer vaccines that introduces an innovative view on monitoring the efficacy as 'patient response' in the form of disease stabilization and prolonged survival rather than strictly adhering to 'tumor response' in the form of Response Criteria In Solid Tumors (RECIST) criteria, since induction and maintenance of host immune response should be the goal of immunotherapies.
69. Eibl B, Schwaighofer H, Nachbaur D et al.: Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88(4), 1501-1508 (1996). ■■ First report on clinical course and in vitro results suggesting that a graft-versus-tumor effect might exist after allogeneic bone marrow transplantation for breast cancer.
70. Ben-Yosef R, Or R, Nagler A, Slavin S: Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 348(9036), 1242-1243 (1996). (Pubitemid 26361619)
71. Ueno NT, Rondon G, Mirza NQ et al.: Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J. Clin. Oncol. 16(3), 986-993 (1998).
72. Khouri IF, Keating M, Korbling M et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J. Clin. Oncol. 16(8), 2817-2824 (1998).
73. Niederwieser D, Maris M, Shizuru JA et al.: Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101(4), 1620-1629 (2003).
74. Sandmaier BM, Mackinnon S, Childs RW: Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol. Blood Marrow Transplant. 13(1 Suppl. 1), 87-97 (2007).
75. Slavin S: Reduced-intensity conditioning or nonmyeloablative stem cell transplantation: introduction, rationale, and historic background. Semin. Oncol. 31(1), 1-3 (2004).
76. Childs RW, Clave E, Tisdale J et al.: Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J. Clin. Oncol. 17(7), 2044-2049 (1999).
77. Childs R, Chernoff A, Contentin N et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343(11), 750-758 (2000). ■■ First publication on graft-versus-tumor effect in a series of 19 patients with metastatic renal cell cancer where nonmyeloablative allogeneic stem cell transplantation induced sustained regression of metastases in ten patients (53%) who have had no response to conventional immunotherapy.
78. Mater Medical Research Institute www.mmri.mater.org.au
79. European Medicines Agency www.emea.eu